STAA News
STAAR Surgical Names Andrew Pilon as Vice President of Business Development
STAAR Surgical Company (STAAR or the Company) (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer Lenses (EVO ICL) for vision correction, today announced the appointment of Andrew Pilon, O.D. as Vice President of Business Development. Dr. Pilon will report...
Business Wire
STAAR Surgical Names Andrew Pilon as Vice President of Business Development
STAAR Surgical Company (STAAR or the Company) (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer Lenses (EVO ICL) for vision correction, today announced the appointment of Andrew Pilon, O.D. as Vice President of Business Development. Dr. Pilon will report...
Business Wire
STAAR Surgical Board Approves $50 Million Share Repurchase Authorization
STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer Lenses (EVO ICL) for vision correction, today announced that its Board of Directors, at a regularly scheduled meeting, authorized a share repurchase program under which the Company...
Business Wire
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of STAAR Surgical Company (NASDAQ: STAA).
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of STAAR Surgical Company (NASDAQ: STAA). SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation...
PR Newswire
STAAR Surgical Releases Landmark Global Report Showing Structural Multi-Market Shift Toward Lens-Based Vision Correction
STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer Lenses (EVO ICL) for vision correction, today released a new report entitled The Future of Refractive Surgery, the first comprehensive global market analysis showing a consistent...
Business Wire
STAAR Surgical Names Former CEO David Bailey as Chief Commercial Officer
STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer Lenses (EVO ICL) for vision correction, today announced the appointment of David Bailey as Chief Commercial Officer. Mr. Bailey will join STAAR's executive...
Business Wire
STAAR Surgical Names Medtech Innovator and Platform Builder Ben Park as Chief Technology Officer
STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer Lenses (EVO ICL) for vision correction, today announced the appointment of Ben Park, Ph.D., as Chief Technology Officer. Dr. Park will join STAAR's...
Business Wire
Deciphering Staar Surgical (STAA) International Revenue Trends
Review Staar Surgical's (STAA) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
Zacks
Here's Why You Should Add Cooper Companies Stock to Your Portfolio Now
Cooper Companies' premium lens migration, MiSight growth and fertility recovery offer long-term upside despite Asia-Pacific, tariff and FX pressures.
Zacks
Staar Surgical (STAA) Surpasses Q2 Earnings and Revenue Estimates
Staar Surgical (STAA) delivered earnings and revenue surprises of +47.62% and +3.05%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
STAAR Surgical Reports Second Quarter 2026 Results
STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer Lenses (EVO ICL) for vision correction, today reported results for the second quarter ended July 3, 2026. Second Quarter 2026 Financial Overview Net sales of $93.5 million, up 111...
Business Wire